Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Synthesis and structure-activity relationships of novel dipeptides and reduced dipeptides as ligands for melanocortin subtype-4 receptor.

Shi Q, Ornstein PL, Briner K, Richardson TI, Arnold MB, Backer RT, Buckmaster JL, Canada EJ, Doecke CW, Hertel LW, Honigschmidt N, Hsiung HM, Husain S, Kuklish SL, Martinelli MJ, Mullaney JT, O'Brien TP, Reinhard MR, Rothhaar R, Shah J, Wu Z, Xie C, Zgombick JM, Fisher MJ.

Bioorg Med Chem Lett. 2006 May 1;16(9):2341-6. Epub 2005 Nov 15.

PMID:
16297618
2.

Synthesis and structure-activity relationships of novel arylpiperazines as potent and selective agonists of the melanocortin subtype-4 receptor.

Richardson TI, Ornstein PL, Briner K, Fisher MJ, Backer RT, Biggers CK, Clay MP, Emmerson PJ, Hertel LW, Hsiung HM, Husain S, Kahl SD, Lee JA, Lindstrom TD, Martinelli MJ, Mayer JP, Mullaney JT, O'Brien TP, Pawlak JM, Revell KD, Shah J, Zgombick JM, Herr RJ, Melekhov A, Sampson PB, King CH.

J Med Chem. 2004 Jan 29;47(3):744-55.

PMID:
14736255
3.

Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 3.

Takeuchi K, Kohn TJ, Honigschmidt NA, Rocco VP, Spinazze PG, Atkinson ST, Hertel LW, Nelson DL, Wainscott DB, Ahmad LJ, Shaw J, Threlkeld PG, Wong DT.

Bioorg Med Chem Lett. 2003 Nov 17;13(22):3939-42.

PMID:
14592479
4.

Advances Toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT(1A) receptor antagonism/SSRI activities. Part 2.

Takeuchi K, Kohn TJ, Honigschmidt NA, Rocco VP, Spinazze PG, Koch DJ, Atkinson ST, Hertel LW, Nelson DL, Wainscott DB, Ahmad LJ, Shaw J, Threlkeld PG, Wong DT.

Bioorg Med Chem Lett. 2003 Jul 21;13(14):2393-7.

PMID:
12824042
5.

Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I.

Pourquier P, Gioffre C, Kohlhagen G, Urasaki Y, Goldwasser F, Hertel LW, Yu S, Pon RT, Gmeiner WH, Pommier Y.

Clin Cancer Res. 2002 Aug;8(8):2499-504.

7.

Excision of 2',2'-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA.

Gandhi V, Legha J, Chen F, Hertel LW, Plunkett W.

Cancer Res. 1996 Oct 1;56(19):4453-9.

8.

Ab initio quantum mechanical and X-ray crystallographic studies of gemcitabine and 2'-deoxy cytosine.

Hausheer FH, Jones ND, Seetharamulu P, Singh UC, Deeter JB, Hertel LW, Kroin JS.

Comput Chem. 1996 Aug;20(4):459-67.

PMID:
8800001
9.

Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine.

Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS.

Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):867-72.

PMID:
8598364
10.

Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models.

Merriman RL, Hertel LW, Schultz RM, Houghton PJ, Houghton JA, Rutherford PG, Tanzer LR, Boder GB, Grindey GB.

Invest New Drugs. 1996;14(3):243-7.

PMID:
8958178
11.

Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells.

Gandhi V, Mineishi S, Huang P, Yang Y, Chubb S, Chapman AJ, Nowak BJ, Hertel LW, Plunkett W.

Semin Oncol. 1995 Aug;22(4 Suppl 11):61-7.

PMID:
7481847
12.

Medicinal chemistry of difluoropurines.

Andis SL, Bewley JR, Boder GB, Burke T, Dudley DE, Eichelberger LE, Grossman CS, Grindey GB, Hertel LW, Jordan CL, et al.

Semin Oncol. 1995 Aug;22(4 Suppl 11):54-60.

PMID:
7481846
13.

Cytotoxicity, metabolism, and mechanisms of action of 2',2'-difluorodeoxyguanosine in Chinese hamster ovary cells.

Gandhi V, Mineishi S, Huang P, Chapman AJ, Yang Y, Chen F, Nowak B, Chubb S, Hertel LW, Plunkett W.

Cancer Res. 1995 Apr 1;55(7):1517-24.

15.

Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells.

Shewach DS, Hahn TM, Chang E, Hertel LW, Lawrence TS.

Cancer Res. 1994 Jun 15;54(12):3218-23.

16.

Effect of a template-located 2',2'-difluorodeoxycytidine on the kinetics and fidelity of base insertion by Klenow (3'-->5'exonuclease-) fragment.

Schy WE, Hertel LW, Kroin JS, Bloom LB, Goodman MF, Richardson FC.

Cancer Res. 1993 Oct 1;53(19):4582-7.

PMID:
8402631
17.
18.

Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts.

Schultz RM, Merriman RL, Toth JE, Zimmermann JE, Hertel LW, Andis SL, Dudley DE, Rutherford PG, Tanzer LR, Grindey GB.

Oncol Res. 1993;5(6-7):223-8.

PMID:
8123942
19.
20.

Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation.

Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W.

Cancer Res. 1992 Feb 1;52(3):533-9.

21.

Action of 2',2'-difluorodeoxycytidine on DNA synthesis.

Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W.

Cancer Res. 1991 Nov 15;51(22):6110-7.

22.

Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.

Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W.

Mol Pharmacol. 1990 Oct;38(4):567-72.

PMID:
2233693
23.

Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).

Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB.

Cancer Res. 1990 Jul 15;50(14):4417-22.

24.

Cytotoxicity and antitumor activity of 2',2'-difluorodeoxycytidine (Gemcitabine).

Grindey GB, Hertel LW, Plunkett W.

Cancer Invest. 1990;8(2):313. No abstract available.

PMID:
2400957
25.
26.

Characterization of the aglycones of the toxic principle of the sea cucumber Holothuria atra.

Delia TJ, Hertel LW, Wittle LW.

Toxicon. 1977;15(5):461-2. No abstract available.

PMID:
906031

Supplemental Content

Loading ...
Support Center